June 2017 - Volume 28 - Issue 5
pp: 469-567

Adriamycin in combination with dexamethasone and octreotide lacks activity on the treatment of a 4T1 metastatic breast cancer model

Dalezis, Panayiotis; Trafalis, Dimitrios T.; Geromichalos, George D.; More

Anti-Cancer Drugs . 28(5):489-502, June 2017.


Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

Benajiba, Lina; Michot, Jean-Marie; Baldini, Capucine; More

Anti-Cancer Drugs . 28(5):540-545, June 2017.

A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient

Botticelli, Andrea; Onesti, Concetta E.; Strigari, Lidia; More

Anti-Cancer Drugs . 28(5):551-556, June 2017.


Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib

Ariyasu, Ryo; Horiike, Atsushi; Koyama, Junji; More

Anti-Cancer Drugs . 28(5):565-567, June 2017.